208 results on '"Qiu, Jiangdong"'
Search Results
2. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer
3. Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancer
4. From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment
5. Single-cell RNA-seq reveals heterogeneity in metastatic renal cell carcinoma and effect of anti-angiogenesis therapy in the pancreas metastatic lesion
6. E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation
7. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer
8. Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis
9. Comprehensive study of clinical features, prognostic factors, and survival in patients with pancreatic solid pseudopapillary neoplasms based on the 2019 WHO classification
10. The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3
11. Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics
12. Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment
13. Organoid: Bridging the gap between basic research and clinical practice
14. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway
15. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models
16. Pre- and post-selected measurements with coupling-strength-dependent modulation
17. A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediate-risk patients after pancreaticoduodenectomy
18. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer
19. Minimally invasive pancreatic surgery: An upward spiral
20. FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis
21. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma
22. Ribosome profiling: a powerful tool in oncological research
23. Targeting hypoxic tumor microenvironment in pancreatic cancer
24. Ultra-precise time tuning and central frequency shift of optical pulses via small weak values
25. NF-κB in pancreatic cancer: Its key role in chemoresistance
26. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory
27. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer.
28. In-situ preparation of core-shell-like scatterers and their effects on optical and mechanical properties of PC-matrix light diffusing materials
29. From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment
30. Role of the microbiome in occurrence, development and treatment of pancreatic cancer
31. Data from OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2
32. Table S1 from OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2
33. Supplementary Materials from OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2
34. Figure S1 from Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models
35. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer
36. Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis.
37. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer
38. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case–control study
39. Cancer-specific survival and metastasis in pancreatic mucinous cystadenocarcinoma: A SEER-based cohort study
40. Meta-analysis of robotic versus open pancreaticoduodenectomy in all patients and pancreatic cancer patients
41. HIF‐1α‐regulated stanniocalcin‐1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway
42. Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics.
43. Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer
44. Manipulating photonic spin accumulation with a magnetic field.
45. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review
46. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells
47. Parameter accuracy analysis of weak-value amplification process in the presence of noise*
48. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer
49. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models
50. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.